Search
forLearn
5 / 801 resultslearn PTD-DBM
learn Tripeptide-1
learn oligopeptide-71
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Research
5 / 483 results
research Investigation the role of SIRT3, SIRT7, NFATC1, and PDL-1 genes in androgenetic alopecia
SIRT3 and SIRT7 genes may play a role in hair loss.
research Investigation the role of SIRT3, SIRT7, NFATC1, and PDL-1 genes in Androgenetic Alopecia
SIRT3 and SIRT7 decrease, while NFATC1 and PDL-1 increase in Androgenetic Alopecia.
research LB1681 Risk of merkel cell carcinoma progression after treatment discontinuation in patients with an objective response to anti-PD-(L)1 immunotherapy
Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.
research Eosinophilic folliculitis of the scalp associated with PD‐1/PDL1 inhibitors
Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.
research Central Centrifugal Cicatricial Alopecia Associated With PDL1 Loss and Increased Expression of Caspase 3: A Case Series
CCCA may involve the PD1/PDL1 pathway and increased caspase 3, leading to permanent hair loss.
Community Join
5 / 1000+ resultscommunity PP405 - hair stem cell stimulation
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
community Pelage are still talking about phase 2a results of PP405
community PP405 Identity Research
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.